BACKGROUND: Approximately 13% of ovarian cancers in Canada are attributable to a mutation in BRCA1 or BRCA2. In 2001, genetic testing for BRCA1 and BRCA2 became freely available to all women in Ontario with a diagnosis of invasive ovarian cancer. It is unknown what proportion of women with ovarian cancer receive genetic testing as a result of this recommendation. METHODS: Patients in Ontario who had been diagnosed with epithelial ovarian cancer from 2002 to 2004 were identified using the Ontario Cancer Registry. Information was collected on demographic and risk factors, including information on previous testing for BRCA1 and BRCA2. Women were asked to provide a blood sample for genetic testing or to provide a genetic test result if clinical testing had been done. Genetic testing for BRCA1 and BRCA2 mutations was conducted on all blood samples. RESULTS: Of the 416 women, 80 women (19%) had undergone previous clinical genetic testing for BRCA1 and BRCA2. Of these 80 women, 30% had a positive genetic test result, compared to 5% of 336 women who had not had clinical genetic testing (p<0.0001). Sixty percent of all mutations were identified within this group of 80 women. CONCLUSIONS: Genetic testing is available in Ontario to all women with invasive ovarian cancer. However, only a small proportion of women are being referred for testing. This study suggests that increased public awareness directed at physicians and at women with cancer may expand the use of genetic testing.
BACKGROUND: Approximately 13% of ovarian cancers in Canada are attributable to a mutation in BRCA1 or BRCA2. In 2001, genetic testing for BRCA1 and BRCA2 became freely available to all women in Ontario with a diagnosis of invasive ovarian cancer. It is unknown what proportion of women with ovarian cancer receive genetic testing as a result of this recommendation. METHODS:Patients in Ontario who had been diagnosed with epithelial ovarian cancer from 2002 to 2004 were identified using the Ontario Cancer Registry. Information was collected on demographic and risk factors, including information on previous testing for BRCA1 and BRCA2. Women were asked to provide a blood sample for genetic testing or to provide a genetic test result if clinical testing had been done. Genetic testing for BRCA1 and BRCA2 mutations was conducted on all blood samples. RESULTS: Of the 416 women, 80 women (19%) had undergone previous clinical genetic testing for BRCA1 and BRCA2. Of these 80 women, 30% had a positive genetic test result, compared to 5% of 336 women who had not had clinical genetic testing (p<0.0001). Sixty percent of all mutations were identified within this group of 80 women. CONCLUSIONS: Genetic testing is available in Ontario to all women with invasive ovarian cancer. However, only a small proportion of women are being referred for testing. This study suggests that increased public awareness directed at physicians and at women with cancer may expand the use of genetic testing.
Authors: Lisa R Susswein; Cécile Skrzynia; Leslie A Lange; Jessica K Booker; Mark L Graham; James P Evans Journal: J Clin Oncol Date: 2008-01-01 Impact factor: 44.544
Authors: Kathleen E Malone; Janet R Daling; David R Doody; Li Hsu; Leslie Bernstein; Ralph J Coates; Polly A Marchbanks; Michael S Simon; Jill A McDonald; Sandra A Norman; Brian L Strom; Ronald T Burkman; Giske Ursin; Dennis Deapen; Linda K Weiss; Suzanne Folger; Jennifer J Madeoy; Danielle M Friedrichsen; Nicola M Suter; Mariela C Humphrey; Robert Spirtas; Elaine A Ostrander Journal: Cancer Res Date: 2006-08-15 Impact factor: 12.701
Authors: R Moslehi; W Chu; B Karlan; D Fishman; H Risch; A Fields; D Smotkin; Y Ben-David; J Rosenblatt; D Russo; P Schwartz; N Tung; E Warner; B Rosen; J Friedman; J S Brunet; S A Narod Journal: Am J Hum Genet Date: 2000-03-16 Impact factor: 11.025
Authors: Harvey A Risch; John R McLaughlin; David E C Cole; Barry Rosen; Linda Bradley; Isabel Fan; James Tang; Song Li; Shiyu Zhang; Patricia A Shaw; Steven A Narod Journal: J Natl Cancer Inst Date: 2006-12-06 Impact factor: 13.506
Authors: T Peelen; M van Vliet; A Bosch; G Bignell; H F Vasen; J G Klijn; H Meijers-Heijboer; M Stratton; G J van Ommen; C J Cornelisse; P Devilee Journal: Br J Cancer Date: 2000-01 Impact factor: 7.640
Authors: Barbara M Norquist; Kathryn P Pennington; Kathy J Agnew; Maria I Harrell; Christopher C Pennil; Ming K Lee; Silvia Casadei; Anne M Thornton; Rochelle L Garcia; Tom Walsh; Elizabeth M Swisher Journal: Gynecol Oncol Date: 2012-12-19 Impact factor: 5.482
Authors: Kathryn Alsop; Sian Fereday; Cliff Meldrum; Anna deFazio; Catherine Emmanuel; Joshy George; Alexander Dobrovic; Michael J Birrer; Penelope M Webb; Colin Stewart; Michael Friedlander; Stephen Fox; David Bowtell; Gillian Mitchell Journal: J Clin Oncol Date: 2012-06-18 Impact factor: 44.544
Authors: Sue V Petzel; Rachel Isaksson Vogel; Tracy Bensend; Anna Leininger; Peter A Argenta; Melissa A Geller Journal: J Genet Couns Date: 2013-05-16 Impact factor: 2.537
Authors: Sue V Petzel; Rachel Isaksson Vogel; Jena McNiel; Anna Leininger; Peter A Argenta; Melissa A Geller Journal: Int J Gynecol Cancer Date: 2014-07 Impact factor: 3.437